Cosmos Holdings Launches New Proprietary Enhanced Dietary Supplement
CHICAGO, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the company") (OTCQX: COSM), a vertically integrated international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and an extensive, established EU distribution network, today announced the launch of a new, proprietary enhanced dietary supplement, Bodyguard, a targeted action formula for strengthening the immune system and reducing fatigue.
Designed and developed by the company’s wholly owned pharmaceutical subsidiary, Doc Pharma S.A., which was founded in Thessaloniki, Greece, in 2015, Bodyguard, which contains Sambucus (elderberry), beta-glucans, vitamin C, zinc, D3, K2 B12, Selenium and Copper, is the newest offering in the Sky Premium Life line of luxury nutritional supplements. Bodyguard, similar to all Sky Premium Life products, is made with the highest quality raw materials and to the highest possible standards, which are in turn based on strict pharmaceutical standards and GMP protocols.
Sambucus, or Elderberry, is a plant known in traditional medicine since antiquity; beta-glucans, are a type of fiber in the form of polysaccharides and are usually derived from plant sources (barley, oats) or from certain types of mushrooms. Vitamin C and Zinc are known to be important factors for the proper functioning of the immune system.
Sky Premium Life Bodyguard:
- contributes to the normal functioning of the immune system
- enhances the body’s energy levels
- reduces fatigue and tiredness
- acts as an antioxidant to protect cells
“We have created unique formulas, with vitamins and herbs, that support specific health needs, a luxury line made with the finest materials, along with a wide range of basic premium quality supplements,” says Greg Siokas, Chief Executive Officer of Cosmos Holdings. “These products promote health and well-being, which we believe are especially important during the Covid-19 pandemic. Sky Premium Life products are available throughout Europe, via our established distribution network, which we have built through relationships with 160+ pharmaceutical wholesale distributors in Europe’s largest markets; we also sell Sky Premium Life supplements directly to 1,500 pharmacies, with access to more than 50,000 pharmacies throughout Europe, and we are looking beyond Europe, as 2021 approaches.”
“Our research and development division has been working all year to develop additional nutraceuticals and supplements for the EU market,” Siokas continued. “Bodyguard is the first, of a number of products, Cosmos will introduce to this market throughout 2021. We expect Bodyguard, and other nutraceuticals and supplements, to contribute substantially to our growth and profitability in 2021.”
Cosmos Holdings will launch a dynamic advertising campaign for Bodyguard, including television with a high-end animation spot, listings in international branded lifestyle magazines like Harper’s Bazaar, Madame Figaro and Vogue, industry magazines, newsletters, advertorials, digital campaigns in social media and via Google AdWords.
, Cosmos Holdings announced the beginning of trading on the OTCQX Best Market. , the company announced its Third Quarter and Nine-Month financial results.
About Cosmos Holdings, Inc.
Cosmos Holdings Inc. is an international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices and an extensive, established EU distribution network. The company identifies, acquires, develops and commercializes products that improve patients' lives and outcomes. Cosmos Holdings has offices and distribution centers in Thessaloniki, Greece and Harlow, UK.
Press Release Disclaimer
Cosmos Holdings, Inc. takes no responsibility for updating the information contained in this press release, following the date hereof to reflect events or circumstances occurring after the date hereof or the occurrence of unanticipated events or for any changes or modifications made to this press release or the information contained herein by any third parties, including, but not limited to, any wire or internet services.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the company, including, but not limited to, the company’s ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic on the company’s business, operations and the economy in general, and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the company’s filings with the SEC, which are available at the SEC’s website (). The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations
Michael J. Porter, President
Porter, LeVay & Rose, Inc.
T: (973) 865-9357
E:
Cosmos Holdings
141 West Jackson Blvd., Suite 4236
CHICAGO, IL 60604
Photos accompanying this announcement are available at:
